Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Your physician will assess your full health picture and design protocols that work together
We present the strategy of utilizing small molecule analogs specifically designed to penetrate the blood-brain barrier and facilitate dimerization and activation of the HGF/Met receptor system
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
What is the difference between NAD+ and 5-amino-1MQ
If you compare it to what we see with GLP-1/GIP therapy, the gap is obvious (more on that below)
US$ 25.10
US$ 24.06
US$ 28.88
US$ 29.02
US$ 21.81
US$ 21.37
US$ 25.38